Abstracts tagged "Clinical practice"

Abstract Number: 1715 • 2015 ACR/ARHP Annual Meeting
Sensivity and Specificity of Clinical Criteria to Identify Patients in Ultrasound Remission in Psoriatic Arthritis
Brigitte Michelsen¹, Andreas P Diamantopoulos², Hilde Berner Hammer³, Arthur Kavanaugh⁴ and Glenn Haugeberg^1,5,6, ¹Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Haugesund Rheumatism Hospital, Haugesund, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴University of California, San Diego School of Medicine, LaJolla, CA, ⁵Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway, ⁶Rheumatology, Martina Hansens Hospital, Gjettum, Norway
Background/Purpose: To date, although several have been proposed, there are no validated remission criteria in psoriatic arthritis (PsA). Validated criteria for minimal disease activity (MDA) in…
Abstract Number: 1717 • 2015 ACR/ARHP Annual Meeting
Factors Associated with the Decision of the Rheumatologist to Order Sacro-Iliac Joints Magnetic Resonance Imaging (SI-MRI) or Order HLA-B27 Testing in Patients with Spondyloarthritis in Clinical Practice
Wilson Bautista-Molano^1,2, Robert Landewé³, Cesar Serna⁴, Rafael R. Valle⁵ and Désirée van der Heijde⁶, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ²Department of Rheumatology, Faculty of Medicine HMC/UMNG, Bogota, Colombia, Bogotá, Colombia, ³Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, The Netherlands, Amsterdam, Netherlands, ⁴Statistics and Mathematics Department, Universidad Central, Bogotá, Colombia, Bogotá, Colombia, ⁵Rheumatology/Immunology, Department of Rheumatology, Faculty of Medicine HMC/UMNG, Bogota, Colombia, Bogota, Colombia, ⁶Dept. of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Magnetic resonance imaging of sacroiliac joints (MRI-SI) and HLA-B27 testing are important tools in the diagnosis of spondyloarthritis (SpA). The aim of the study…
Abstract Number: 1977 • 2015 ACR/ARHP Annual Meeting
Long-Term Survival of Methotrexate in Giant Cell Arteritis Patients in Clinical Practice
Dalifer Freites Núñez¹, Zulema Rosales^1,2, Lucía Arietti¹, Leticia Leon², Inmaculada Morado¹, Benjamín Fernández-Gutiérrez³, Luis Rodriguez-Rodriguez², Juan A Jover¹ and Lydia Abasolo², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ³Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: It has is been demonstrated the safety and efficacy of Methotrexate (MTX) in the treatment of Giant Cell Arteritis (GCA) in clinical trials, but…
Abstract Number: 2107 • 2015 ACR/ARHP Annual Meeting
Initiation of Combination Triple Therapy in Real World Clinical Practice Rarely Replicates the Protocols Used in Randomized Controlled Trials.
Grant W. Cannon¹, Chia-Chen Teng², Ted R. Mikuls³, Jeffrey R. Curtis⁴, Derek Tang⁵, Bradley S. Stolshek⁵ and Brian Sauer⁶, ¹Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ³Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT
Background/Purpose: Combination therapy with methotrexate (MTX), sulfasalazine (SUL), and hydroxychloroquine (HCQ) [triple therapy] is an effective treatment for rheumatoid arthritis (RA). Randomized controlled trials…
Abstract Number: 117 • 2015 ACR/ARHP Annual Meeting
Same Day Rheumatology Access Clinic in an Academic Health Care Center
Muhammad Ijaz^1,2, Alireza Meysami¹, Amita Bishnoi¹ and Bernard Rubin³, ¹Rheumatology, Henry Ford Hospital, Detroit, MI, ²Rheumatology, Wayne State University/Detroit Medical Center, Detroit, MI, ³Rheumatology, Henry Ford Health System, Detroit, MI
Background/Purpose: Open access clinics have been studied extensively in the primary care setting 1, but there is limited data regarding rheumatology open access clinics. To…
Abstract Number: 2418 • 2015 ACR/ARHP Annual Meeting
Pediatric Enthesitis-Related Arthritis: Variation in Disease Characteristics and Treatments Among 5 Large Centers
Sabrina Gmuca¹, Timothy Brandon², Rui Xiao³, Ilaria Pagnini⁴, Tracey B. Wright⁵, Timothy Beukelman⁶, Esi Morgan-DeWitt⁷ and Pamela F. Weiss⁸, ¹Pediatric Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ²Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, ³Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ⁴Department of Paediatrics, University of Florence and Anna Meyer Children's Hospital, Florence, Italy, Florence, Italy, ⁵Pediatrics/Rheumatology, Univ of TX Southwestern, Dallas, TX, ⁶Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Pediatric rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: We aimed to compare the clinical features and treatments of children with Enthesitis-related arthritis (ERA) from 5 pediatric rheumatology centers in order to determine…
Abstract Number: 132 • 2015 ACR/ARHP Annual Meeting
Delivering a One-Stop, Integrated, Patient-Centred Service for Patients with Rheumatic Diseases. the Finnish Approach
Elena Nikiphorou¹, Paula Väre¹, Kirsi Paalanen¹, Jelena Borodina¹, Arto Kokko², Pekka Hannonen¹ and Tuulikki Sokka-Isler³, ¹Jyvaskyla Central Hospital, Jyvaskyla, Finland, ²Jyvaskyla Central Hospital, Jyväskylä, Finland, ³Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland
Background/Purpose: Rheumatology is mainly an outpatient specialty. Prompt diagnosis & treatment to prevent long-term disability in an integrated, multi-disciplinary approach to care are crucial. In reality though,…
Abstract Number: 2489 • 2015 ACR/ARHP Annual Meeting
Effects of Two Interventions on Rheumatologists Adherence to Optimal Care Recommendations in Rheumatoid Arthritis: A Combined before/after and Randomized Controlled Trial
Nienke Lesuis¹, Ronald van Vollenhoven², Marlies Hulscher³ and Alfons den Broeder¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²ClinTRID, Department of Medicine, Karolinska Institute, Stockholm, Sweden, ³IQ Healthcare, Radboud University Medical Centre, Nijmegen, Netherlands
Background/Purpose: Current treatment guidelines for rheumatoid arthritis (RA) recommend using tight control strategies.1 Despite evidence for the benefits of this strategy, physician adherence is suboptimal.2,3…
Abstract Number: 185 • 2015 ACR/ARHP Annual Meeting
Success Rate and Utility of Ultrasound Guided Synovial Biopsies in Clinical Practice
Aurélie Najm, Benoît Le Goff and Yves Maugars, Rheumatology, Rheumatology, Nantes, France
Background/Purpose: Histological and bacteriological analysis of synovial tissue (ST) can be useful in the diagnosis of arthritis of undetermined origin. Ultrasound can assist this biopsy…
Abstract Number: 2612 • 2015 ACR/ARHP Annual Meeting
Impact of a Multibiomarker Disease Activity Score in Patients with Rheumatoid Arthritis Treated in a Real World Setting
Sergio Schwartzman¹, Keith Knapp², Gary Craig³, Karen Ferguson⁴ and Howard Kenney⁵, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Arthritis Northwest, Spokane, WA, ³Discus Analytics, Inc., Spokane, WA, ⁴Arthritis Northwest PLLC., Spokane, WA, ⁵Rheumatology, Arthritis Northwest, Spokane, WA
Background/Purpose: A number of composite outcome measures have been validated to quantify disease activity in Rheumatoid Arthritis (RA). Few studies have been published on the…
Abstract Number: 256 • 2015 ACR/ARHP Annual Meeting
The Predominant Attack Type and Associated Clinical-Laboratory Conditions in Patients with Familial Mediterranean Fever
Mustafa Cakar¹, Muharrem Akhan², Muhammet Cinar¹ and Sedat Yılmaz¹, ¹Rheumatology, Gulhane Medical Faculty, Ankara, Turkey, ²Internal Medicine, Gulhane Medical Faculty, Ankara, Turkey
Background/Purpose: Familial Mediterranean Fever (FMF) is an autoinflammatory disease characterized by recurrent attacks of fever and serositis. Abdominal pain is the most frequent symptom of…
Abstract Number: 2666 • 2015 ACR/ARHP Annual Meeting
Trajectories of EQ-5D in RA Patients Treated with Biologics Using the IORRA Cohort
Daisuke Hoshi, Eiichi Tanaka, Eisuke Inoue, Yoko Shimizu, Naoki Sugimoto, Kumi Shidara, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Patient-reported outcomes are recognized as important for evaluating the disease status of rheumatoid arthritis (RA). The EuroQol 5-dimensional descriptive system (EQ-5D) has been used…
Abstract Number: 433 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA) Biologic Switching and Cycling in a Large US Managed Care Population
Machaon Bonafede¹, Jeffrey R. Curtis², Donna McMorrow¹, Chieh-I Chen³ and George J. Joseph⁴, ¹Truven Health Analytics, Cambridge, MA, ²Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Global Health Economics & Outcomes Research (HEOR), Sanofi, Bridgewater, NJ
Background/Purpose: A majority of RA patients who switch from a tumor necrosis factor inhibitor (TNFi) to another biologic disease-modifying anti-rheumatic drug (DMARD) are TNFi cyclers…
Abstract Number: 2729 • 2015 ACR/ARHP Annual Meeting
Clinical and Radiographic Outcome of Iguratimod for Rheumatoid Arthritis
Tsuneo Kondo, Akiko Shibata, Ryota Sakai, Jun Kikuchi, Kentaro Chino, Ayumi Okuyama, Hirofumi Takei and Koichi Amano, Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
Background/Purpose: Iguratimod is a new small-molecular drug for rheumatoid arthritis (RA), which was approved on June, 2012 in Japan. The agent inhibits the production of…
Abstract Number: 448 • 2015 ACR/ARHP Annual Meeting
A Majority of Early Rheumatoid Arthritis (ERA) Patients Reach Remission By 6 Months in Usual Rheumatology Care
Tuomas Rannio¹, Juha Asikainen², Pekka Hannonen³, Timo Yli-Kerttula⁴, Päivi Ekman⁵, Laura Pirilä⁶, Markku Mali⁷, Laura Kuusela⁷, Maija Puurtinen-Vilkki⁷, Saara Kortelainen⁸, Johanna Paltta⁷, Kirsi Taimen⁷, Heidi Mäkinen⁹, Pia Isomäki⁹, Terhi Uotila⁹, Markku J. Kauppi¹⁰, Kari Laiho¹¹, Satu Nyrhinen¹¹, Tuulikki Sokka-Isler¹ and FIN-ERA study group, ¹Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ²Jyväskylä Central Hospital, Jyväskylä, Finland, ³Jyvaskyla Central Hospital, Jyvaskyla, Finland, ⁴Sairaalantie 3, Central Hospital of Satakunta, Pori, Finland, ⁵Central Hospital of Satakunta, Pori, Finland, ⁶Tyks, P.O. Box 52, Turku University Central Hospital, Turku, Finland, ⁷Turku University Central Hospital, Turku, Finland, ⁸Alvar Aallontie 275, Turku University Central Hospital, Turku, Finland, ⁹Tampere University Hospital, Tampere, Finland, ¹⁰Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ¹¹Päijät-Häme Central Hospital, Lahti, Finland
Background/Purpose: Finnish national combination treatment trials have demonstrated excellent outcomes in patients with ERA including 90% of patients reaching DAS28 remission at 6 months. Whether…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.